Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (23431)	7/22/1998 11:26:00 AM
From: Russian Bear	Read Replies (1) \| Respond to of 32384

Everyone, There appears to be a persistent seller of the warrants out there. They are now remarkably cheap, relative to the common. BTW, their last bottom (around 5.5, several months ago,) was followed by a near-double, in short order. Good luck, RB

To: Hippieslayer who wrote (23431)	7/22/1998 12:36:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Have you no sense of observation? >> Like you, I have a great ability to observe previous stock movements. << With the news that lgnd has put out this stock has done nothing except drift downwards since the LLY deal. There was a period where it started to climb but then it went down >> Sad but true. I am impressed in your observation abilities! <g> << The problem, as it appears to me, is that you are emotionally involved with this stock and I that you are unwilling to look at it in a rational manner. >> I am emotionally involved with any money I have left after payday. It has been a long ongoing love affair, but unfortunatly short lived! <g> You are saying that I don't look at LGND in a rational manner. Yet, I discuss issues related to the company. You only talk about "previous" stock movements. Previous trends are important, but if you invest based on previous stock movements only, which is which it seems, you might consider putting your pennies in a sock, instead of investing them. For instance, how do you feel about Ligand's corporate plan for "off label" marketing? I think that it is brilliant. That plan, plus their deep pipeline, is to what I am emotionally attached. << Lgnd looks to have a bright future, but at the moment, it's dead. >> So, at this moment it is dead. Hence you have sold your shares. But, it's got a bright future?! Sounds like a real great reason for selling. Hmmmmm!? Oh, I forgot. You like to invest by looking backwards! <g> << Why is that so hard for you to understand? Just because you don't like what I say doesn't mean it isn't valid. >> I will never understand racism. I have a low tolerance for hate, but strong motivation towards justice. << Okay smartguy, you tell me why lgnd is at it's present price and looking to yet set any solid base? >> Biotechs have been the whipping boys of the market. LGND is not alone. There are many biotechs that are languishing. Have you no sense of observation? <g> << Let me tell you something. LGND is overpriced as it is. >> I think that you are seriously wrong on this point. But, you are not a shareholder, and I am. Even though we are adversaries, I hope that you don't miss the LGND plane, when it takes off. << I still like the company but would rather take my risks somewhere else. >> Like the company? Please don't get emotional attached to it! <g> Good luck with your non-LGND investments. I'm sure everyone on this thread will be pulling for you! <g> Bob

To: Hippieslayer who wrote (23431)	7/22/1998 1:16:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Speaking of being observant.... You've been doing a lot of boohooing about Targretin causeing Regression of Tamoxifen-Resistant Breast Cancer Tumors in mice. What good is it, if it only being tested in rats, right? Wrong! You want to know why? Here's why: <==================================================================== "Ligand is conducting three pivotal trials for the treatment of patients with cutaneous T-cell lymphoma, including one Phase III trial with Targretin gel (bexarotene) 1.0% and two Phase II/III trials with Targretin capsules. Phase II/III trials are being conducted with Targretin capsules in patients with advanced lung cancer, and Phase IIb studies are in progress in patients with ovarian, head and neck cancer and Kaposi's sarcoma. Targretin gel is also being tested in a Phase II trial for the treatment of patients with actinic keratoses." =====================================================================> In other words, Targretin has already had positive clinical results from Targretin in humans. This is what I think that Wall Street is missing. A lot of new drugs pass the "mice" test, and then fail the human test. But, in Targretin's case, it is also being tested in humans, but not for the same cancer: "An interim assessment of the Phase I/II study for Targretin Gel in CTCL in March 1997 demonstrated that 43% (18 of 42) of patients showed a 50% or greater improvement in this disease." "Findings for advanced stage CTCL patients only, who received higher dose Targretin Capsules showed a 43% (9 of 21) response." "Targretin Capsules are also in advanced clinical studies in a variety of other cancers". So, what do we have here? Ligand is preparing NDA's for small population diseases, where there is no available, effective treatment, so that they can try for "fast track" approval by the FDA. In the mean time they have geared up clinical trials for other diseases. Very nice, no? So, even though Targretin works on breast cancer in mice only, at this time, it's credibility, that it might also work in humans, is enhanced by successes in human clinical trials for other cancers. "The presentation included new data based on preclinical animal models that show the efficacy of Targretin in causing complete regression of breast cancer tumors that are resistant to the drug tamoxifen." Yes, I am emotional involved with this stock! Regards, Bob